Corcept股价上涨,因其卵巢癌药物在中期研究中取得积极结果

路透中文
Oct 26
BUZZ-Corcept股价上涨,因其卵巢癌药物在中期研究中取得积极结果

10月26日 - ** Corcept Therapeutics(CORT.O)股价在盘前交易中上涨3%,至87.23美元

** 该生物技术公司表示,其卵巢癌药物Lifyorli与化疗药物纳米白蛋白包被紫杉醇(nab-paclitaxel)及贝伐珠单抗联合使用,在铂类耐药性卵巢癌患者中显示出积极疗效

** 该公司补充称,在一项涉及95名患者的研究中,该治疗方案使中位无进展生存期达到7.2个月,客观缓解率为59%

** 此前未接受过贝伐珠单抗治疗的患者疗效更佳,中位无进展生存期为8.1个月,客观缓解率达66%——CORT

** 数据显示,6个月时88%的患者仍存活;在主要分析时,中位总生存期尚未达到

** 截至上一交易日收盘,该股年内累计涨幅约147%

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10